The 35 references in paper E. Petrosyan K., T. Belyanskaya V., L. Ilienko I., A. Tsygin N., V. Nosikov V., Е. Kamyshova S., Э. Петросян К., Т. Белянская В., Л. Ильенко И., А. Цыгин Н., В. Носиков В., Е. Камышова С. (2006) “ПОЛИМОРФНЫЙ МАРКЕР 4G/5G ГЕНА PAI-1 У ДЕТЕЙ С ХРОНИЧЕСКИМ ГЛОМЕРУЛОНЕФРИТОМ // POLYMORPHIC MARKER 4G/5G OF GENE PAI-1 IN CHILDREN WITH CHRONIC GLOMERULONEPHRITIS” / spz:neicon:nefr:y:2006:i:4:p:56-61

1
Ратнер МЯ, Серов ВВ, Томилина НА. Ренальные дис­ функции. Медицина, М., 1977; 254
(check this in PDF content)
2
Тареева ИВ. Нефрология. Руководство для врачей. Медицина, М., 2000; 236-248
(check this in PDF content)
3
Чиж АС. Современные представления об этиологии и патогенезе диффузного гломерулонефрита. Здравоохр Белоруссии 1972; 4: 2-6
(check this in PDF content)
4
Шахмалова МШ, Шестакова МВ, Чугунова ЛА, Дедов ИИ. Вазоактивные факторы эндотелия сосудов у больных инсулин-независимых сахарным диабетом с поражением почек. Тер архив 1996; (6): 43-45
(check this in PDF content)
5
Feng L, Tang WW, Loskutoff DJ, Wilson CB. Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis. J Am Soc Nephrol 1992; 3: 1753-1764
(check this in PDF content)
6
Besbas N, Erbay A, Saatci U et al. Trombomodulin, tissue plasminogen activator inhibitor-1 in Henoch-Scholein purpura. Clin Exp Rheumatol 1998; 16: 95-98
(check this in PDF content)
7
Allisone A. Eddy. Plasminogen activator inhibitor -1 and the kidney. Am J Physiol Renal Physiol 2002; 283: 209-220
(check this in PDF content)
8
Xu Y, Hagege J, Mougenot B et al. Different expression of the plasminogen activator system in renal trombotic microangiopathy and the normal human kidney. Kidney Int 1996; 50: 2011-2019
(check this in PDF content)
9
Duymelinck C, Dauwe SHE, De Greef KEJ et al. TIMP 1 gene expression and PAI_1 antigen after unilateral obstruction in the adult male rat. Kidney Int 2000; 58: 1186-1201
(check this in PDF content)
10
Duymelinck C, Dauwe SHE, De Greef KEJ et al. TIMP 1 gene expressionvand PAI_1 antigen after unilateral obstruction in the adult male rat. Kidney Int 2000; 58: 1186-1201
(check this in PDF content)
11
Guan L, Ji X, Wang J et al. Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19: 393-396
(check this in PDF content)
12
Oda T, Jung YO, Kim H et al. PAI-1 deficiency attenuates the fibrinogenic response to ureteral obstruction. Kidney Int 2001; 30: 587-596
(check this in PDF content)
13
Brooun NJ, Nakamura S, Ma L et al. Aldesterone modulates plasminogen activator, inhibitor -1 and glomerulosclerosis in vivo. Kidney Int 2000; 58:1219-1227
(check this in PDF content)
14
Oikawa T, Freeman M, Lo W et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibitor. Kidney Int 1997; 51: 164-172
(check this in PDF content)
15
Ma LJ, Nakamura S, Whitssitt JS et al. Regression of sclerosis in anging by an angiotensin inhibitor-iduced decrease in PAI-1. Kidney Int 2000; 58: 2425-2436
(check this in PDF content)
16
Tamaki K, Okuda S, Nakayama M et al. Transforming growth factor -beta 1 in hypertensive renal injury in Dahl salt- sensitive rats. J Am Soc Nephrol 1996; 7: 2578-2589
(check this in PDF content)
17
Eddy AA. Interstitial inflammation, and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 1996; 50: 1139-1149
(check this in PDF content)
18
Keeton M, Eguchi Y, Sawadey M et al. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1993; 142: 59-70
(check this in PDF content)
19
Sugatani J, Igarashi T, Manucata M et al. Activator of coagulation in C57BL/6 mice given verotoxin 2 ( VT 2) and the effect of co-administration of LPS with VT 2. Tromb Res 2000; 100: 61-72
(check this in PDF content)
20
Haraguchi M, Border WA, Huang Y, Noble NA. t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. Kidney Int 2001; 59: 2146-2155
(check this in PDF content)
21
Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-p in experimental chronic cyclosporine nephropathy. Kydney Int 1996; 49: 1141-1151
(check this in PDF content)
22
Sihab FS, Bennett WM, Tanner AM, Andoh TF. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64: 1829-1837
(check this in PDF content)
23
Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992; 42: 1462-1469
(check this in PDF content)
24
Hamano K, Iwano M, Akai Y et al. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002; 30: 695-705
(check this in PDF content)
25
Yamamoto T, Noble NA, Cohen AH et al. Expression of transforming growth factor p isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469
(check this in PDF content)
26
Yamaamoto T, Nakamura T, Noble NA et al. Expression of transforming growth factor p is elevated in human and experimental diabetic nephropathy. Proc Nath Acad Sci USA 1993; 90: 1814-1818
(check this in PDF content)
27
Stegnar M, Uhrin P, Peternel P et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998; 79: 975­ 979
(check this in PDF content)
28
Gilles P, Bosson JL, Golshayan D et al. The diamant alpin dialys cohort study: Clinico-biological characteristics and cardiovascular genetic risk profile of incendent patients. J Nephrol 2004; 17: 66-75
(check this in PDF content)
29
Grubic N, Stegnar M, Peternel P et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996;15:431-443
(check this in PDF content)
30
Gong R, Liu Z, Chen Z, Li L. Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002; 19: 1-5
(check this in PDF content)
31
Wang AY, Poon P, Lai FM et al. Plasminogen activator inhibitor -1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001; 59: 1520-1528
(check this in PDF content)
32
Suzuki H, Sakuma Y, Kanesaki Y. Close relationship of plasminogen activator inhiditor-1 4G/5G polymorphism and progression of Ig-A nephropathy. Clin Nephrol 2004; 62: 173­ 179
(check this in PDF content)
33
Приходина ЛС, Заклязьминская ЕВ, Полтавец НВ и др. Полиморфизм гена ингибитора активатора плазмино­ гена-1 у детей с гормонорезистентным нефротическим синдромом^! Съезд науч.об-ва нефрологов. Сборник те­ зисов; 2005: 43
(check this in PDF content)
34
Margaglione M, Cappucci G, d’Addedda M et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562-567
(check this in PDF content)
35
Tang WW, Feng L, Xia Y, Wilson CB. Extracellular matrix accumulation in immune-mediated tubulointerstitial injury. Kidney Int 2003; 45: 1077-1084 Поступила в редакцию 06.09.2006 г.
(check this in PDF content)